AVRICORE HEALTH INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.17 CAD | 0.00% |
|
+9.68% | 0.00% |
| 30/04 | Avricore Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04/04 | Avricore's HealthTab Signs Agreement for More Rexall Pharmacy Locations | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4.01 | 1.574 | 6.64 | 15.61 | 31.26 | 16.94 |
| Enterprise Value (EV) 1 | 3.926 | 1.582 | 7.339 | 13.63 | 30.67 | 16.69 |
| P/E ratio | -0.82 x | -0.67 x | -4.89 x | -8.67 x | -37.7 x | -24.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 17.7 x | 47.7 x | 201 x | 127 x | 17.7 x | 4.86 x |
| EV / Revenue | 17.3 x | 47.9 x | 222 x | 111 x | 17.3 x | 4.79 x |
| EV / EBITDA | -1.5 x | -1.07 x | -7.89 x | -7.87 x | -64.3 x | -95.9 x |
| EV / FCF | -5.57 x | 19.6 x | -6.94 x | -15.9 x | -25 x | -326 x |
| FCF Yield | -18% | 5.1% | -14.4% | -6.3% | -4% | -0.31% |
| Price to Book | 4.53 x | -3.38 x | -9.29 x | 7.1 x | 15.9 x | 8.43 x |
| Nbr of stocks (in thousands) | 40,104 | 52,473 | 69,896 | 97,535 | 99,245 | 99,645 |
| Reference price 2 | 0.1000 | 0.0300 | 0.0950 | 0.1600 | 0.3150 | 0.1700 |
| Announcement Date | 30/05/19 | 29/04/20 | 29/04/21 | 22/04/22 | 01/05/23 | 30/04/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.2264 | 0.033 | 0.033 | 0.1228 | 1.768 | 3.485 |
| EBITDA 1 | -2.617 | -1.485 | -0.9304 | -1.731 | -0.4773 | -0.174 |
| EBIT 1 | -3.153 | -1.603 | -1.049 | -1.746 | -0.6536 | -0.5856 |
| Operating Margin | -1,392.25% | -4,858.04% | -3,175.64% | -1,421.52% | -36.96% | -16.8% |
| Earnings before Tax (EBT) 1 | -4.137 | -1.916 | -1.174 | -1.708 | -0.8182 | -0.7012 |
| Net income 1 | -4.137 | -2.106 | -1.174 | -1.708 | -0.8182 | -0.7012 |
| Net margin | -1,826.85% | -6,380.63% | -3,554.24% | -1,390.9% | -46.27% | -20.12% |
| EPS 2 | -0.1221 | -0.0445 | -0.0194 | -0.0184 | -0.008361 | -0.007043 |
| Free Cash Flow 1 | -0.705 | 0.0807 | -1.058 | -0.8584 | -1.227 | -0.0512 |
| FCF margin | -311.34% | 244.4% | -3,202.8% | -699.01% | -69.36% | -1.47% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 30/05/19 | 29/04/20 | 29/04/21 | 22/04/22 | 01/05/23 | 30/04/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.01 | 0.7 | - | - | - |
| Net Cash position 1 | 0.08 | - | - | 1.97 | 0.59 | 0.25 |
| Leverage (Debt/EBITDA) | - | -0.005113 x | -0.7511 x | - | - | - |
| Free Cash Flow 1 | -0.71 | 0.08 | -1.06 | -0.86 | -1.23 | -0.05 |
| ROE (net income / shareholders' equity) | -244% | -911% | 199% | -230% | -39.3% | -35.3% |
| ROA (Net income/ Total Assets) | -96.1% | -142% | -202% | -80.2% | -16.8% | -14.3% |
| Assets 1 | 4.304 | 1.48 | 0.5806 | 2.13 | 4.858 | 4.892 |
| Book Value Per Share 2 | 0.0200 | -0.0100 | -0.0100 | 0.0200 | 0.0200 | 0.0200 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0.0200 | 0.0100 | 0 |
| Capex 1 | 0.01 | - | - | 0.11 | 1.19 | 1.02 |
| Capex / Sales | 2.21% | - | - | 85.79% | 67.48% | 29.31% |
| Announcement Date | 30/05/19 | 29/04/20 | 29/04/21 | 22/04/22 | 01/05/23 | 30/04/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 12.41M | |
| +31.82% | 695B | |
| +26.51% | 568B | |
| -4.66% | 361B | |
| +19.56% | 330B | |
| +3.67% | 283B | |
| +16.85% | 239B | |
| +8.78% | 204B | |
| -7.77% | 198B | |
| +8.75% | 168B |
- Stock Market
- Equities
- AVCR Stock
- Financials Avricore Health Inc.